^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Pancreatic Adenocarcinoma

    Related cancers:
    1m
    Efficacy and Tolerability of Zenocutuzumab in Advanced NRG1 Fusion-Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial. (PubMed, J Clin Oncol)
    Zenocutuzumab demonstrated clinically meaningful and durable antitumor activity with a favorable safety profile in patients with advanced NRG1+ cholangiocarcinoma.
    P2 data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • NRG1 (Neuregulin 1)
    |
    NRG1 fusion
    |
    Bizengri (zenocutuzumab-zbco)
    1m
    1911GCCC: Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P2, N=15, Active, not recruiting, University of Maryland, Baltimore | Trial completion date: Dec 2027 --> Dec 2026
    Trial completion date
    |
    gemcitabine
    1m
    Early Metastatic Relapse in Resected Stage IB KRAS G12D Pancreatic Ductal Adenocarcinoma: Limitations of Anatomical Staging. (PubMed, Cureus)
    Despite apparently favorable pathological staging and adjuvant FOLFIRINOX chemotherapy, the patient developed early biochemical progression with rapidly rising carbohydrate antigen 19-9 (CA 19-9) levels, followed by widespread metastatic dissemination involving the liver, lung, spine, skeletal muscle, and multiple visceral sites...This case highlights the limitations of anatomical staging in PDAC and emphasizes the prognostic importance of tumor biology, including KRAS mutation status, lymphovascular invasion, and perineural invasion. It also demonstrates the potential limitations of CA 19-9 as a solitary marker of treatment response in biologically aggressive disease.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12D • KRAS G12
    |
    5-fluorouracil • irinotecan • leucovorin calcium
    1m
    Use of liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in neoadjuvant pancreatic adenocarcinoma: NEO-Nal-IRI trial. (PubMed, Oncologist)
    Neoadjuvant NALIRIFOX is a safe and active regimen in R/BR PDAC with a low post-operative complication rate, high treatment completion and R0 resection rates, and meaningful clinical responses. These findings support further investigation of NALIRIFOX as part of a total neoadjuvant therapy (TNT) approach in PDAC. [ClinicalTrials.gov identifier: NCT03483038].
    Journal
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    5-fluorouracil • oxaliplatin • leucovorin calcium • Onivyde (nanoliposomal irinotecan)
    1m
    GIANT: Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread (clinicaltrials.gov)
    P2, N=176, Active, not recruiting, ECOG-ACRIN Cancer Research Group | Trial primary completion date: Jun 2026 --> Mar 2026
    Trial primary completion date
    |
    UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    gemcitabine • albumin-bound paclitaxel • leucovorin calcium • Onivyde (nanoliposomal irinotecan) • fluorouracil topical
    1m
    A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer (clinicaltrials.gov)
    P1, N=20, Recruiting, Memorial Sloan Kettering Cancer Center
    New P1 trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12D • KRAS G12S
    |
    Tevimbra (tislelizumab-jsgr) • oxaliplatin • irinotecan • ELI-002 7P
    2ms
    Metabolic Reprogramming and Microenvironment in Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P=N/A, N=64, Recruiting, Institut Paoli-Calmettes
    New trial
    2ms
    Alpha Radiation Emitters Device (DaRT) for the Treatment of Locally Advanced Pancreatic Cancer (clinicaltrials.gov)
    P=N/A, N=40, Recruiting, Alpha Tau Medical LTD. | Not yet recruiting --> Recruiting
    Enrollment open
    2ms
    Early onset pancreatic Cancer: epidemiology, molecular features, and clinical outcomes. (PubMed, Cancer Treat Rev)
    The substantial hereditary and potentially actionable molecular burden supports universal germline testing and comprehensive tumour genomic profiling, particularly in younger patients and in KRAS wild-type disease. PARP inhibitors should be described as improving progression-free survival or disease-control outcomes in selected BRCA-mutated metastatic PDAC rather than as having established a statistically significant overall survival benefit.
    Clinical data • Review • Journal • BRCA Biomarker • PARP Biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • BRCA (Breast cancer early onset)
    |
    KRAS wild-type • RAS wild-type • BRCA mutation
    2ms
    SIL204SL-P001: SIL204-SL Treatment for Locally Advanced Pancreatic Cancer (2025-525157-39-00)
    P2/3, N=10, Not yet recruiting, Silexion Therapeutics Ltd.
    New P2/3 trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    2ms
    PLATINUM-CAN: Study of NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic Cancer (clinicaltrials.gov)
    P2/3, N=10, Active, not recruiting, University Health Network, Toronto | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • CA 19-9 (Cancer antigen 19-9)
    |
    PALB2 mutation
    |
    cisplatin • gemcitabine • albumin-bound paclitaxel
    2ms
    OLIGOMETS: Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels (clinicaltrials.gov)
    P2, N=54, Recruiting, Yale University | Initiation date: Mar 2026 --> Jun 2026
    Trial initiation date • Circulating tumor DNA